EXPERTS IN IMMUNOTHERAPY

COMPANY HISTORY

APEIRON was founded in 2003 by Josef Penninger to translate academic basic research into therapeutic products in diseases with high unmet need, namely cancer. The operations of the Company started in 2005, initially focusing on discovery projects. Since its inception, APEIRON has substantially devoted its resources to raising capital and developing innovative projects. The Company has since inception identified and developed potential product candidates and conducts pre-clinical and clinical trials in different tumor indications.

On 1 January 2022 the operational R&D activities of APEIRON were spun off into invIOs GmbH, including all staff and related assets.

Leadership Team

PLD_150x200

Peter Llewellyn-Davies

Chief Executive Officer, Chief Financial Officer (CEO/CFO)
More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as Advisory roles in companies to execute exit strategies .Peter joined APEIRON Biologics in 2017 and is founding president of BIOTECH AUSTRIA, the Austrian Biotechnology Association.
AGE-150x200

Andreas Gerber

Chief Operating Officer (COO)
Andreas Gerber, PhD, has multiple years of experience in the pharmaceutical industry.
Before joining APEIRON Biologics, he served as Site Head & Executive Director Biologics
and Vaccines Formulation at Merck Sharpe & Dohme. Previously, he was responsible for
the development of various active pharmaceutical ingredients and their production at
Novartis Austria and managed a production site for biologics in Kundl, Austria. Andreas
received his PhD from the University of Basel and an Executive MBA from the University of St. Gallen.
RGU_150x200

Romana Gugenberger

Chief Medical & Scientific Officer (CMSO)
Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and worked several years at the Medical University of Vienna in the field of Cardiovascular Research and Tumor Biology. Since 11 years she works at APEIRON Biologics and supports non-clinical and clinical projects. At the moment she is leading the APN401 – APEIRON´s autologous cellular therapy.

Supervisory Board

MRE-150x200-1

Manfred Reichl, PhD, JD, MSc

Chairman
Entrepreneur, investor, business angel ("Austrian Business Angel of the Year 2009"), and Senior Adviser to renowned global institutions (e.g. UBS Investment Bank, World Economic Forum). More than 20 years of experience in international strategic consulting as Senior Managing Partner at Roland Berger, heading Austria and Eastern Europe for more than 15 years. European Program Manager for a Computer Line at Hewlett Packard. Lecturer in Vienna respectively Munich on "Corporate Governance", "China", and "Globalization".
ERA-150x200-1

Erwin Rasinger, MD

Austrian physician and politician. Studied Medicine and Business Administration in Vienna. Referee for ecology of the Medical Association of Austria. Member of Austrian National Assembly from 1994 until 2017.
UGR_150x200

Ulrich Granzer, PhD

Independent consultant with currently 40 employees focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products and small molecules including orphan products.
He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies).
HSC-150x200

Helmut Schuehsler, PhD

Dr. Schuehsler led the creation of TVM Capital Healthcare in the United Arab Emirates in 2009, and in Singapore 2018, after he had joined the TVM Capital group of companies in Munich in 1990. Helmut has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health and life science market, and more than 50 IPOs and 30 M&A exit transactions.
ECH-150x200

Edward D. Charles

A rounded finance professional, spending the first twenty years in banking where he was responsible for several derivatives trading books and then ran the European structured finance departments at J P Morgan, Credit Suisse and Bank of America. He has, in the last fifteen years, founded multiple financial businesses; including in the asset management, financial advisory and insurance underwriting arenas. For the last twenty years he has been a keen Private Equity investor in both the biotech and fintech industries and the Treasurer of Docklands Outreach, a London based charity. He holds a Masters from University College, Oxford in Politics, Philosophy and Economics and a Masters in Modern and Contemporary Literature from Birkbeck College, London.